02/10/2026 Biogen reported 52-week Phase 2 data for litifilimab in CLE Biogen reported 52-week Phase 2 data for litifilimab in CLE (Ref) Biogen reported 52-week results from the Phase 2 portion (Part A) of the ongoing Phase 2/3 AMETHYST study of litifilimab (BIIB059; anti-BDCA2 mAb) showing continued improvement in cutaneous lupus erythematosus (CLE). 27.2% of patients achieved clear or almost clear skin (CLA-IGA 0–1) at Week 52, while 28.8% achieved CLASI-70. Patients who

23/09/2026 Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy Immunovant’s IMVT-1402 failed to meet the primary endpoint in CLE Roche’s sefaxersen significantly reduced proteinuria in IgA nephropathy (Ref) Roche reported positive prespecified interim results from Ph3 IMAgINATION study of sefaxersen (ASO targeting complement factor B) in adults with primary IgA nephropathy (IgAN). The trial met its primary endpoint, demonstrating statistically significant

28/03/2026 Biogen announced Phase 2 results for litifilimab for CLE Results from Sanofi’s Phase 3 studies in AD were presented AAD Alumis announced Phase 3 data for envudeucitinib for plaque psoriasis Incyte announced Phase 3 data for povorcitinib for HS Biogen announced Phase 2 results for litifilimab for CLE ( Ref ) Biogen announced positive results from part A of its Phase2/3 AMETHYST/ NCT05531565 study, which evaluated litifilimab (BDCA2) for the treatment of patients w